0.379
0.00 (-0.16%)
| Penutupan Terdahulu | 0.380 |
| Buka | 0.385 |
| Jumlah Dagangan | 340,340 |
| Purata Dagangan (3B) | 794,207 |
| Modal Pasaran | 11,270,214 |
| Harga / Jualan (P/S) | 1.74 |
| Harga / Buku (P/B) | 2.27 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Operasi (TTM) | -330.18% |
| EPS Cair (TTM) | -2.80 |
| Nisbah Semasa (MRQ) | 2.55 |
| Aliran Tunai Operasi (OCF TTM) | -24.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -16.53 M |
| Pulangan Atas Aset (ROA TTM) | -915.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -78,814.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | GeoVax Labs, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.25 |
|
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.42% |
| % Dimiliki oleh Institusi | 7.72% |
| Julat 52 Minggu | ||
| Median | 6.00 (1,481.44%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 19 Nov 2025 | 6.00 (1,481.44%) | Beli | 0.415 |
| 26 Sep 2025 | 9.00 (2,272.17%) | Beli | 0.646 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |